卡培他滨治疗对氟脲嘧啶耐药晚期转移性结、直肠癌的效果观察

Capecitabine for 5-Fu-resistant metastatic colorectal cancer

目的观察卡培他滨治疗对氟脲嘧啶耐药的晚期转移性结、直肠癌的疗效.方法选择47例对5-氟尿嘧啶（5-FU）耐药的晚期转移性结、直肠癌病人接受卡培他滨（希罗达）治疗,根据WHO标准评价疗效及毒性反应.结果本组总有效率为17.0%,平均反应持续时间为8.5个月,原病情进展的病人有44.7%经治疗后病情稳定,病情稳定的平均时间4.8个月.有50%病例在5个月内存在病情不再进展,自应用希罗达后平均生存期为10.4个月,治疗前体重持续下降病人经3个周期治疗有83.0%（39/47）体重稳定或增加.毒性反应中以恶心、腹泻、食欲减退、疲劳、手足综合征最为常见.结论对5-FU产生耐药性的晚期结、直肠癌病人,经希罗达治疗后仍有较高的有效率,而且毒性反应可以耐受,不影响继续治疗.

AIM To investigate the therapeutic efficacy of capecitabine in 5 - Fu- resistant metastatic colorectal cancer. METHODS Forty- seven patients with documented progressive colorectal cancer were treated with capecitabine daily for 14 days. RESULTS The overall response rate was 8/47 （ 17.0% ）, and 44.7% patients achieved disease stabilization for a period of 4.8 months. CONCLUSION Progressive colorectal cancer can be hampered by capecitabine by a couple of months to show some effect.